<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02630914</url>
  </required_header>
  <id_info>
    <org_study_id>14 7424 15</org_study_id>
    <nct_id>NCT02630914</nct_id>
  </id_info>
  <brief_title>Medical and Surgical Hybrid Treatment of Atrial Fibrillation.</brief_title>
  <acronym>HT2AF</acronym>
  <official_title>Medical and Surgical Hybrid Treatment of Atrial Fibrillation: Epicardial and Endocardial Combined Approach.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to investigate the feasibility of a hybrid procedure removal of
      the atrial fibrillation.

      This is a single procedure for both surgical epicardial by minimally invasive route
      (Thoracoscopy) without even flow controlled and supplemented if necessary by extra corporeal
      intracavitary route at the same time.

      This faster procedure combined with complete lesions have a higher success rate and less
      frequent re-hospitalizations of patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with complete procedure or not</measure>
    <time_frame>3 hours</time_frame>
    <description>At the end of the intervention, the doctor evaluates whether the procedure was complete with electric exclusion of the posterior wall of the left atrium and the 4 pulmonary veins.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of atrial fibrillation episode</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke Rate</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization for heart failure</measure>
    <time_frame>12 months</time_frame>
    <description>The number of hospitalizations for heart failure after hybrid procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Quality of life (EQ-5D according to the survey-3L)</measure>
    <time_frame>12 months</time_frame>
    <description>The quality of life will be measured using the EQ-5D 3L questionnaire (EQ-5D according to the survey-3L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The cost-effectiveness ration</measure>
    <time_frame>12 months</time_frame>
    <description>Cost estimates will be conducted from the perspective of health insurance. The expenses incurred in the care of patients will be counted during the follow-up year.
The effectiveness will be assessed against the complications of strategy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Atrial Fibrillation (AF)</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will have the hybrid procedure of ablation of atrial fibrillation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>The AtriCure Synergy Ablation System</intervention_name>
    <description>The AtriCure Synergy Ablation System will be used on all patients for AF ablation.</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        patients with complex AF defined by the following criteria :

          -  AF&gt; 1 week or long term persistent&gt; 1 year

          -  AND Symptomatic

          -  AND after failure of treatment of anti-arrhythmic or against-indication for
             anti-arrhythmic

        Exclusion Criteria:

        The exclusion criteria are relevant contraindications thoracoscopy or the non-complex
        nature of the AF:

          -  Paroxysmal AF or AF cardioverted anti-arrhythmic test (unless against indicated)

          -  Recent AF for which a simple gesture is intracavitary considered sufficient

          -  Permanent AF

          -  Asymptomatic AF

          -  Very old AF (&gt; 5 years) or atrial major ectasia (&gt; 60 mm)

          -  Need another surgery (valve bypass coronary)

          -  Previous history of sternotomy or thoracotomy

          -  High-risk surgical or anesthetic Patient

          -  BMI&gt; 35

          -  Sleep Apnea

          -  Ejection fraction &lt;35%

          -  Thoracic trauma history

          -  Veins Pulmonary stenosis&gt; 50%

          -  Hyperthyroidism

          -  Thrombus in LAA
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bertrand Marcheix, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Toulouse</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bertrand Marcheix, MD</last_name>
    <phone>0561323718</phone>
    <phone_ext>+33</phone_ext>
    <email>marcheix.b@chu-toulouse.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Etienne Grunenwald, MD</last_name>
    <phone>0561323078</phone>
    <phone_ext>+33</phone_ext>
    <email>grunenwald.e@chu-toulouse.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Toulouse</name>
      <address>
        <city>Toulouse</city>
        <state>Midi Pyrenees</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bertrand Marcheix, MD</last_name>
      <phone>0561323718</phone>
      <phone_ext>+33</phone_ext>
      <email>marcheix.b@chu-toulouse.fr</email>
    </contact>
    <contact_backup>
      <last_name>Etienne Grunenwald, MD</last_name>
      <phone>05 61323078</phone>
      <phone_ext>+33</phone_ext>
      <email>grunenwald.e@chu-toulouse.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Bertrand Marcheix, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Etienne Grunenwald, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne Rollin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe Maury, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery, Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010 Oct;31(19):2369-429. doi: 10.1093/eurheartj/ehq278. Epub 2010 Aug 29. Erratum in: Eur Heart J. 2011 May;32(9):1172.</citation>
    <PMID>20802247</PMID>
  </reference>
  <reference>
    <citation>Rich MW. Epidemiology of atrial fibrillation. J Interv Card Electrophysiol. 2009 Jun;25(1):3-8. doi: 10.1007/s10840-008-9337-8. Epub 2009 Jan 22. Review.</citation>
    <PMID>19160031</PMID>
  </reference>
  <reference>
    <citation>Pison L, Gelsomino S, Luc√† F, Parise O, Maessen JG, Crijns HJ, La Meir M. Effectiveness and safety of simultaneous hybrid thoracoscopic and endocardial catheter ablation of lone atrial fibrillation. Ann Cardiothorac Surg. 2014 Jan;3(1):38-44. doi: 10.3978/j.issn.2225-319X.2013.12.10.</citation>
    <PMID>24516796</PMID>
  </reference>
  <reference>
    <citation>Pison L. Breakthroughs in hybrid management of stand-alone AF. Ann Cardiothorac Surg. 2014 Jan;3(1):78-9. doi: 10.3978/j.issn.2225-319X.2013.12.05.</citation>
    <PMID>24516802</PMID>
  </reference>
  <reference>
    <citation>Gelsomino S, Van Breugel HN, Pison L, Parise O, Crijns HJ, Wellens F, Maessen JG, La Meir M. Hybrid thoracoscopic and transvenous catheter ablation of atrial fibrillation. Eur J Cardiothorac Surg. 2014 Mar;45(3):401-7. doi: 10.1093/ejcts/ezt385. Epub 2013 Jul 31. Review.</citation>
    <PMID>23904136</PMID>
  </reference>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2015</study_first_submitted>
  <study_first_submitted_qc>December 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2015</study_first_posted>
  <last_update_submitted>December 15, 2015</last_update_submitted>
  <last_update_submitted_qc>December 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Epicardial surgical removal</keyword>
  <keyword>Closure of the left atrial</keyword>
  <keyword>Left atrial appendage (LAA)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

